Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Targeted Treatment of Skin Inflammation
share announcement

Targeted Treatment of Skin Inflammation

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 1065

Special Issue Editors

Prof. Dr. Paola Savoia

E-Mail Website
Guest Editor
Department of Health Science, University of Eastern Piedmont, 13100 Novara, Italy
Interests: melanoma; non-melanoma skin cancer; skin carcinogenesis mechanisms; organ transplant recipients; primary cu-taneous lymphomas
Dr. Elisa Zavattaro

E-Mail Website
Guest Editor
Department of Health Science, University of Eastern Piedmont, 13100 Novara, Italy
Interests: non-melanoma skin cancer; field cancerization; organ transplant recipients; melanoma
Special Issues, Collections and Topics in MDPI journals
Dr. Federica Veronese

E-Mail Website
Guest Editor
Department of Dermatology, Azienda Ospedaliera Maggiore della Carita di Novara, 28100 Novara, Italy
Interests: non-melanoma skin cancer; skin carcinogenesis mechanisms; organ transplant recipients; atopic dermatitis

Special Issue Information

Dear Colleagues,

This Special Issue aims to provide a comprehensive overview of the latest advancements and emerging trends in the field of dermatology. This Special Issue also seeks to explore innovative approaches and therapeutic strategies for effectively managing skin inflammation. We invite researchers, clinicians, and experts in the field to contribute original research articles, reviews, and clinical studies that shed light on targeted treatment options for various skin inflammatory conditions. The Special Issue aims to cover a wide range of topics, including but not limited to:

  1. Mechanisms of skin inflammation and immune response;
  2. Novel drug delivery systems for targeted therapy;
  3. Diagnostic tools for assessing skin inflammation;
  4. Clinical trials and evidence-based treatment approaches.

We welcome original research articles, comprehensive reviews, and meta-analyses that provide valuable insights into the targeted treatment of skin inflammation. However, please note that this Special Issue will not consider mini-reviews or case reports.

We look forward to receiving your contributions and thank you for your support.

Prof. Dr. Paola Savoia
Dr. Elisa Zavattaro
Dr. Federica Veronese
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • atopic dermatitis
  • acne vulgaris
  • contact dermatitis
  • eczema
  • urticaria
  • cutaneous lupus erythematosus
  • pustular disorders

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

19 pages, 763 KiB  
Review
Topical Treatments in Atopic Dermatitis: An Expansive Review
by Michelle Lazar, Aurore D. Zhang and Neelam A. Vashi
J. Clin. Med. 2024, 13(8), 2185; https://doi.org/10.3390/jcm13082185 - 10 Apr 2024
Viewed by 518
Abstract
Atopic dermatitis (AD) is a common inflammatory skin condition found worldwide. It impacts patient quality of life (QoL) and is thought to arise as an inflammatory response to epidermal barrier dysfunction and hypersensitivity. AD can lead to large out-of-pocket costs and increased healthcare [...] Read more.
Atopic dermatitis (AD) is a common inflammatory skin condition found worldwide. It impacts patient quality of life (QoL) and is thought to arise as an inflammatory response to epidermal barrier dysfunction and hypersensitivity. AD can lead to large out-of-pocket costs and increased healthcare expenses over a lifetime. An analysis of all randomized control trials conducted since 1990 on topical therapies for AD were reviewed, including 207 trials in the final analysis. It was found that an average of 226 patients were enrolled over 2.43 arms. Common topical treatments included corticosteroids, calcineurin inhibitors, JAK inhibitors, and phosphodiesterase inhibitors. The most utilized tools to identify treatment efficacy were the EASI, IGA, SCORAD, and PGA. There was a paucity of data on trials that evaluated efficacy, QoL, and cost of treatment simultaneously. This review highlights the need for comprehensive trials that evaluate multiple aspects of treatment, including financial cost and QoL impact, to ensure each patient has the best treatment modality for the management of their AD. Full article
(This article belongs to the Special Issue Targeted Treatment of Skin Inflammation)
►▼ Show Figures

Figure 1

Other

Jump to: Review

9 pages, 589 KiB  
Case Report
Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature
by Nicoletta Bernardini, Luca Ambrosio, Ersilia Tolino, Ilaria Proietti, Nevena Skroza and Concetta Potenza
J. Clin. Med. 2024, 13(8), 2250; https://doi.org/10.3390/jcm13082250 - 12 Apr 2024
Viewed by 362
Abstract
Background/Objectives: Treating psoriasis patients requires the consideration of potential underlying complications like latent viral infections and chronic kidney disease, which may influence therapy selection. Case presentation: A patient with end-stage kidney disease (ESKD) undergoing hemodialysis (HD) was successfully treated with bimekizumab, [...] Read more.
Background/Objectives: Treating psoriasis patients requires the consideration of potential underlying complications like latent viral infections and chronic kidney disease, which may influence therapy selection. Case presentation: A patient with end-stage kidney disease (ESKD) undergoing hemodialysis (HD) was successfully treated with bimekizumab, an IgG1 humanized monoclonal antibody inhibiting interleukin (IL)-17A and IL-17F. This case appears to be the first documented instance of effective anti-IL-17A/IL-17F antibody treatment in a psoriasis patient undergoing HD, with a sustained positive response for eight months. Discussion: Studies indicate the comparable pharmacokinetics, efficacy, and safety of certain psoriasis drugs in patients with chronic kidney disease (CKD) and those with normal renal function. The positive clinical outcome observed following treatment with bimekizumab aligns with the existing literature on this topic. However, further studies are needed to objectively evaluate the pharmacokinetics, efficacy, and safety of this drug in this specific setting. Conclusions: This documented case represents the first known use of bimekizumab to treat psoriasis in patients undergoing dialysis, suggesting its potential effectiveness and safety in this population. Full article
(This article belongs to the Special Issue Targeted Treatment of Skin Inflammation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop